BRC Therapeutics Appoints Kimberly Spancake as Senior Director, Clinical

Clinical Trial Leader Brings More Than 25 Years of Experience in Drug Development at GW Pharmaceuticals, Jazz Pharmaceuticals, and other companies

MONTEREY, Calif., Nov. 5, 2026 /PRNewswire/ -- BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing therapeutics for neurological and inflammatory conditions, today announced that Kimberly Spancake, Ph.D., has joined the company as Senior Director, Clinical. Spancake has spent more than 25 years in drug development and has run clinical trials from early through late stages. Her industry experience spans many modalities and includes deep domain expertise in cannabinoid-based clinical programs gained at GW Pharmaceuticals and its U.S. subsidiary, Greenwich Biosciences. At BRC, she will lead clinical operations across the company's programs as they progress through their development.

Dr. Spancake joins BRC from Jazz Pharmaceuticals, where she has served as Director, Risk Management and Monitoring since 2023. In that role, her team built the framework Jazz uses today to manage risk and quality in its clinical trials, including its central monitoring strategy. Dr. Spancake also oversaw the global clinical monitoring teams associated with both internally run trials and those trials run by CROs. As Director of Clinical Operations, she led the clinical trial managers and specialists running the nabiximols (Sativex®) programs that Jazz acquired from GW Pharmaceuticals in 2021.

"Kim Spancake brings deep clinical operations experience from GW Pharmaceuticals and Jazz Pharmaceuticals, gained from the pivotal studies that supported FDA approvals and other essential studies," said George Hodgin, Founder and CEO of BRC Therapeutics. "The quality of our programs in CRPS, AIIA and RLS, and the clinical data generated to date, give us a strong foundation. Kim's leadership will be central as we work toward our next regulatory and clinical milestones, each of which brings us one step closer to potential approval and to our ultimate goal of delivering meaningful new treatment options to patients."

"We are delighted to welcome Kim to BRC," said Justyna Kulpa, Ph.D., Head of Research and Development at BRC. "She has the critical experience to orchestrate and oversee clinical trials across multiple sites while holding every study to the highest standards of quality and data integrity. Her leadership will strengthen our clinical execution as our programs grow, and I look forward to working closely with her."

"I've seen what BRC has built: rigorous science, a strong pipeline and a clear regulatory path for medicines in conditions where patients have too few options," said Kimberly Spancake. "I'm excited to join the team and to help drive the company's next set of development milestones with the precision and oversight these programs deserve."

Spancake holds a Ph.D. in Human Genetics from the University of Utah and completed a postdoctoral fellowship at the Huntsman Cancer Institute. She started her industry career at Incyte and then assumed roles of increasing responsibility in clinical operations and strategy at Cato Research, a regulatory and clinical research organization (now Allucent). Kim also served as a visiting scientist at Lawrence Berkeley Laboratory. She earned her B.S. in Biology, magna cum laude, from Dickinson College.

BRC Therapeutics (BRC) is a pharmaceutical company focused on developing innovative therapeutics to deliver relief from pain and other symptoms in chronic conditions. BRC's medicines are multimodal and contain cannabinoids at defined ratios. BRC has developed a pipeline of investigational prescription medicines addressing neurological and inflammatory conditions. Investigational products are currently being tested in clinical trials for Complex Regional Pain Syndrome (CRPS), Restless Legs Syndrome (RLS), and Aromatase Inhibitor-Induced Arthralgia (AIIA) and an additional confidential indication. BRC is registered with the Drug Enforcement Administration and is based in Monterey, CA.

To learn more about BRC, visit https://brctherapeutics.com/.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks, uncertainties and assumptions, including without limitation statements about the development, use, benefits and effects of BRC Therapeutics' (BRC) therapeutic product candidates and related technology, future plans for BRC's business and growth, and expected plans with respect to clinical trials, including the number of patients enrolled and timing of patient enrollment. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "design," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements. The forward-looking statements made herein speak only as of the date of this press release and, unless otherwise required by law, BRC does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

SOURCE BRC Therapeutics